Semaglutide
InjectionWeight Loss
InjectionWeight LossIn stock
Zepbound® injection
Branded tirzepatide approved specifically for chronic weight management in adults with obesity or overweight + comorbidity. Run a Zepbound®-aware program with intake, billing, refill, and pharmacy workflows wired into one backend.
Dose
Once weekly
Avg. loss · 72 wks
−20.9%
Format
Weekly subcutaneous pen or vial
Dose range
2.5 mg to 15 mg once weekly
Rx required
Yes, licensed provider review
Indication
Chronic weight management in obesity
About the medication
A high-efficacy weight-loss brand built on tirzepatide
Zepbound® is Eli Lilly's branded once-weekly tirzepatide approved for chronic weight management in adults with obesity or overweight + comorbidity. In the SURMOUNT-1 trial, adults with obesity lost an average of 20.9% of body weight at 72 weeks on the 15 mg dose.
- Same molecule as Mounjaro® but FDA-labeled specifically for chronic weight management
- Dual GIP and GLP-1 agonism gives a higher efficacy ceiling than semaglutide brands
- 91% of SURMOUNT-1 participants on 15 mg achieved at least 5% weight loss
- Strong fit for clinics that want a premium GLP-1 program with higher weight-loss expectations
Mechanism
Dual GIP and GLP-1 receptor agonist
Delivery
Pre-filled pen or vial, once weekly subcutaneous
Onset
Appetite changes during escalation, weight loss builds over 24 to 72 weeks
Oversight
Every order routed through a licensed provider review
Expected results
The highest weight-loss ceiling among approved branded GLP-1s
Based on SURMOUNT-1 outcomes at 72 weeks. Real-world results depend on tolerated maintenance dose, titration adherence, lifestyle changes, and individual response.
20.9%
Avg. total body weight loss
at 72 weeks, 15 mg dose
91%
Patients losing ≥5%
at week 72 on 15 mg
57%
Patients losing ≥20%
at week 72 on 15 mg
Mean change in body weight
% change from baseline · weeks 0–68
Zepbound® 15 mgPlacebo
At week 68
−20.9%
Zepbound® 15 mg
At week 68
−3.1%
Placebo
Net difference
−17.8 pts
vs. placebo
Illustrative, based on published SURMOUNT-1 outcomes for Zepbound® 15 mg. Real-world results depend on tolerated maintenance dose, titration adherence, lifestyle changes, and individual response.
Dosing protocol
Standard titration schedule
Zepbound® labeling starts at 2.5 mg weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on the current dose.
- 1Weeks 1–42.5 mgInitiation dose
- 2Weeks 5–85 mgFirst escalation step
- 3Weeks 9–127.5 mgOptional step-up if tolerated
- 4Weeks 13–1610 mgCommon mid-program maintenance
- 5Weeks 17–2012.5 mgHigher-dose escalation
- 6Week 21+15 mgMaximum labeled maintenance dose
The Turbopills stack for this program
Everything you need to run a Zepbound® program
Pick the pieces you want. Use your own brand, your own providers, your own price, powered by a single, compliant backend.
Product website & ad landing pages
Turbopills AI Studio — ad images & videos
BetaProvider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Experiments & A/B tests
BetaReady to launch
Ship a Zepbound® program in weeks, not quarters.
The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.
Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.
Trademark notice. Zepbound® is a registered trademark of Eli Lilly and Company. Turbopills is not affiliated with, endorsed by, or sponsored by Eli Lilly. References to the brand are for educational and operator-scoping purposes only.
Related
